|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, the present study on the first Italian series of thyroid cancers shows a frequency of 38.3% of BRAF(V599E) in the classical variant of PTC, confirming the key role of this mutation in promoting tumourigenesis.
|
15272920 |
2004 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These data clearly confirm that BRAF(V599E) is the more common genetic alteration found to date in adult sporadic PTCs, that it is unique for this thyroid cancer histotype, and that it might drive the development of PTCs of the classic papillary subtype.
|
15126572 |
2004 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These data clearly confirm that BRAF(V599E) is the more common genetic alteration found to date in adult sporadic PTCs, that it is unique for this thyroid cancer histotype, and that it might drive the development of PTCs of the classic papillary subtype.
|
15126572 |
2004 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, the present study on the first Italian series of thyroid cancers shows a frequency of 38.3% of BRAF(V599E) in the classical variant of PTC, confirming the key role of this mutation in promoting tumourigenesis.
|
15272920 |
2004 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF provides signals crucial for proliferation of thyroid carcinoma cells spontaneously harboring the (V600E)BRAF mutation and, therefore, BRAF suppression might have therapeutic potential in (V600E)BRAF-positive thyroid cancer.
|
16533790 |
2006 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
They also potently blocked MEK phosphorylation in human thyroid cancer cell lines with either RET/PTC1 (TPC1) or BRAF(V600E) (NPA, ARO, and FRO) mutations.
|
16551863 |
2006 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The BRAF(V600E) mutation was present in 93 (83%) of 112 thyroid cancers.
|
17054470 |
2006 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
They also potently blocked MEK phosphorylation in human thyroid cancer cell lines with either RET/PTC1 (TPC1) or BRAF(V600E) (NPA, ARO, and FRO) mutations.
|
16551863 |
2006 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The BRAF(V600E) mutation was present in 93 (83%) of 112 thyroid cancers.
|
17054470 |
2006 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF provides signals crucial for proliferation of thyroid carcinoma cells spontaneously harboring the (V600E)BRAF mutation and, therefore, BRAF suppression might have therapeutic potential in (V600E)BRAF-positive thyroid cancer.
|
16533790 |
2006 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
After treatment with the potent MEK 1/2 inhibitor AZD6244, MEK inhibition and cell growth were examined in four BRAF mutant (V600E) and two BRAF wild-type thyroid cancer cell lines and in xenografts from a BRAF mutant cell line.
|
17878251 |
2007 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Small molecule inhibitors that selectively target B-Raf(V600E) may provide clinical benefit for patients with thyroid cancer.
|
17363500 |
2007 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas.
|
17714762 |
2007 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E mutation status was determined in 347 tumor samples from 314 patients with thyroid cancer (245 with conventional papillary thyroid cancer, 73 with follicular thyroid cancer, and 29 with the follicular variant of papillary thyroid cancer).
|
17717450 |
2007 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas.
|
17387744 |
2007 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas.
|
17387744 |
2007 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas.
|
17714762 |
2007 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Small molecule inhibitors that selectively target B-Raf(V600E) may provide clinical benefit for patients with thyroid cancer.
|
17363500 |
2007 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E mutation status was determined in 347 tumor samples from 314 patients with thyroid cancer (245 with conventional papillary thyroid cancer, 73 with follicular thyroid cancer, and 29 with the follicular variant of papillary thyroid cancer).
|
17717450 |
2007 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
After treatment with the potent MEK 1/2 inhibitor AZD6244, MEK inhibition and cell growth were examined in four BRAF mutant (V600E) and two BRAF wild-type thyroid cancer cell lines and in xenografts from a BRAF mutant cell line.
|
17878251 |
2007 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF((V600E)) mutation is the most frequent genetic alteration in papillary thyroid carcinomas (PTCs) that are 80-90% of all thyroid cancers.
|
18310287 |
2008 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF(V600E) mutation, in both primary and metastatic thyroid cancers, is associated with a marked drop in thyroperoxidase (29-fold) and pendrin (20-fold) expression and a considerable increase (five-fold) in GLUT-1 expression.
|
17854396 |
2008 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF(V600E) mutation, in both primary and metastatic thyroid cancers, is associated with a marked drop in thyroperoxidase (29-fold) and pendrin (20-fold) expression and a considerable increase (five-fold) in GLUT-1 expression.
|
17854396 |
2008 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF((V600E)) mutation is the most frequent genetic alteration in papillary thyroid carcinomas (PTCs) that are 80-90% of all thyroid cancers.
|
18310287 |
2008 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In many cancers, including thyroid cancer, B-Raf(V600E) appears to play a crucial role in cell proliferation, survival and de-differentiation.
|
19356676 |
2009 |